LOS ANGELES, CA / ACCESSWIRE / January 30, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Zimmer Biomet Holdings, Inc. (“Zimmer” or the “Company”) (NYSE: ZBH) concerning possible violations of federal securities laws between September 7, 2016 and October 31, 2016 inclusive (the “Class Period”). Investors, who purchased or otherwise acquired Zimmer shares during the Class Period, are encouraged to contact the firm in advance of the January 31, 2016 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

Per the complaint, during the Class Period, Zimmer made materially false and/or misleading statements, as well as failed to disclose material adverse facts about its business, operations, and prospects. The complaint is as follows: that issues within the supply chain caused a decline in order fulfillment, particularly within the knee and hip portfolios; that, because of this, Zimmer would not achieve its revenues and profit as anticipated and; that as a result of the above, the Company’s statements regarding its business, operations, and prospects were false and misleading and/or lacked a reasonable basis.

On October 31, 2016, the Company issued a press release reporting third quarter 2016 financial results. Zimmer reported net sales of $1.83 billion, and lowered guidance for the full year 2016 at $7.630 billion to $7.650 billion, a decline from the $7.68 billion to $7.715 billion estimated in July. Zimmer maintains that weak sales are due to a change in the supply chain, leading to a lack of available implants and instrument sets during the quarter.

In a conference with investors following the above release, the Company stated: “Third quarter revenue was below our expectations, primarily due to execution issues within our large joint supply chain, which led to a degradation in order fulfillment rates late in the quarter as well as our performance in dental…As a consequence, we underestimated demand for certain key cross-sell brands within our existing customer base, leading to a depletion of our safety stocks and also affecting our ability to capitalize on new customer opportunities.”

Following this, shares of Zimmer fell $17.15 per share, or nearly 14%, to close on October 31, 2016 at $105.40 per share, causing investors serious harm.

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

Lundin Law PC was established by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding the rights of shareholders.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 453829

IRVINE, CA / ACCESSWIRE / January 30, 2017 / Khang & Khang LLP (the “Firm”) announces a class action lawsuit against Zimmer Biomet Holdings, Inc. (“Zimmer” or the “Company”) (NYSE: ZBH). Investors, who purchased or otherwise acquired shares between September 7, 2016 and October 31, 2016 inclusive (the “Class Period”), are encouraged to contact the Firm in advance of the January 31, 2017 lead plaintiff motion deadline.

If you purchased shares of Zimmer during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

The complaint states that during the Class Period, Zimmer made materially false and/or misleading statements, as well as failed to disclose material adverse facts about its business, operations, and prospects. The complaint alleges the following: that issues within the supply chain caused a decline in order fulfillment, particularly within the knee and hip portfolios; that, because of this, Zimmer would not realize its revenues and profit as expected and; that as a result of the above, the Company’s statements regarding its business, operations, and prospects were false and misleading and/or lacked a reasonable basis.

On October 31, 2016, the Company sent a press release reporting third quarter 2016 financial results. Zimmer reported net sales of $1.83 billion, and lowered guidance for the full year 2016 at $7.630 billion to $7.650 billion, a decline from the $7.68 billion to $7.715 billion estimated in July. Zimmer claims weak sales are due to a change in the supply chain, leading to a lack of available implants and instrument sets during the quarter.

In a phone meeting with investors after the above release, the Company stated: “Third quarter revenue was below our expectations, primarily due to execution issues within our large joint supply chain, which led to a degradation in order fulfillment rates late in the quarter as well as our performance in dental…As a consequence, we underestimated demand for certain key cross-sell brands within our existing customer base, leading to a depletion of our safety stocks and also affecting our ability to capitalize on new customer opportunities.”

Shares of Zimmer fell $17.15 per share, or nearly 14%, to close on October 31, 2016 at $105.40 per share, causing investors harm.

If you wish to learn more about this lawsuit, at no charge to you, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in certain jurisdictions.

Contact:

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 453828

NEW YORK, NY / ACCESSWIRE / January 30, 2017 / Levi & Korsinsky announces that it has commenced an investigation of Centennial Resource Development, Inc. (NASDAQ: CDEV) concerning possible breaches of fiduciary duty by the board of directors of the company. To obtain additional information about the investigation, go to: http://zlk.9nl.com/centennial-CDEV, or contact Eduard Korsinsky, Esq. either via email at ek@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Eduard Korsinsky, Esq.
30 Broad Street – 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 453831

IRVINE, CA / ACCESSWIRE / January 30, 2017 / Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against BT Group plc (“BT Group” or the “Company”) (NYSE: BT). Investors, who purchased or otherwise acquired BT Group shares between May 23, 2013, and January 23, 2017, inclusive (the “Class Period”), are encouraged to contact the firm in advance of the March 27, 2017 lead plaintiff deadline.

If you purchased shares of BT Group plc during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

On January 24, 2017, BT Group announced a profit warning and revealed that it was lowering its guidance for 2017 and 2018, due to an investigation into the accounting practices at its Italian company. When this information was revealed to the investing public, the value of BT Group fell, causing investors serious harm.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

If you wish to learn more about this lawsuit, at no charge, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contact:

Khang & Khang LLP
Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 453815

NEW YORK, NY / ACCESSWIRE / January 30, 2017 / HempAmericana, Inc. (OTC PINK: HMPQ) is pleased to announce its first foray into the Cannabinoids (CBD’s) oil extraction business. A Section 3(a)(10) of the Securities Act of 1933 transaction with an institutional investor valued at approximately $265,000 allowed HempAmericana to acquire an extraction system from Infinity Supercritical LLC. On the eve of its transaction with Blackbridge Capital (who is committing up to $20 Million Dollars in a Tier-I Reg A+ financing), the Company is now poised to explore CBD oils contained in hemp plants.

“Our deal with Infinity Supercritical is our first step towards building an extraction laboratory,” said Salvador Rosillo, CEO of HempAmericana, Inc. “HempAmericana plans to be a leader in the industrial exploration of the over ten types of oil contained in the hemp plant.”

HempAmericana is currently in the rolling paper and CBD oil business using the brand name, “Weed Got Oil.” Search “Rolling Thunders hemp papers” on Youtube for a product demonstration of the Company’s papers. The Company now plans to become a leader in the CBD oil market by establishing a laboratory for the extraction and research of the oils contained in the hemp plant. HempAmericana also researches, develops, and sells products made of industrial hemp. See more at http://www.HempAmericana.com and http://wwwHempAmericana.net.

The Company chose Infinity Supercritical because its CO2 technology is food safe, byproduct-free, and environmentally friendly, which can help HempAmericana develop research for the many health benefits of CBDs. CBD’s by themselves are not psychoactive, like the component THC which is found in Cannabis, and is used for medical marijuana. The extracted oil, amongst other uses, can be used for food additives, cosmetics, and medical uses.

Safe Harbor Provision

Cautionary statement for purposes of the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995: Information in this news release contains forward-looking statements that involve risks, uncertainties, and assumptions. If such risks or uncertainties materialize or such assumptions prove incorrect, the results of the Company and its consolidated subsidiaries could differ materially from those expressed or implied by such forward-looking statements and assumptions. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Risks, uncertainties, and assumptions include the execution and performance of contracts by the Company and its customers, suppliers, and partners. Please also review HempAmericana’s annual and quarterly financials for a more complete discussion of risk factors. The Company disclaims any obligation to update or revise statements contained in this news release based on new information or otherwise.

SOURCE: HempAmericana, Inc.

ReleaseID: 453823

NEW YORK, NY / ACCESSWIRE January 30, 2017 / The following statement is being issued by Levi & Korsinsky, LLP:

To: All Persons or Entities who purchased Ixia (NASDAQ: XXIA) stock prior to January 30, 2017.

You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Ixia to Keysight Technologies, Inc. (NYSE: KEYS) for $19.65 per share. To learn more about the action and your rights, go to: http://zlk.9nl.com/xxia, or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut, California, and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
30 Broad Street – 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 453825

NEW YORK, NY / ACCESSWIRE / January 30, 2017 / The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired securities of Fenix Parts, Inc. (NASDAQ: FENX) between May 14, 2015 and October 12, 2016. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the District of New Jersey. To get more information, go to: http://www.zlk.com/pslra/fenix-parts-inc, or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Fenix had an inadequate inventory valuation methodology; (2) Fenix had an inadequate methodology to calculate goodwill impairment; (3) Fenix was engaging and/or had engaged in conduct that would result in an SEC investigation; and (4) as a result, Defendants’ statements about Fenix’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

If you suffered a loss in Fenix, you have until March 13, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street – 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 453822

LOS ANGELES, CA / ACCESSWIRE / January 30, 2017 / Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Banc of California, Inc. (“Banc of California” or the “Company”) (NYSE: BANC) concerning possible violations of federal securities laws between October 29, 2015 and January 20, 2017 inclusive (the “Class Period”). Investors, who purchased or otherwise acquired shares during the Class Period, should contact the firm prior to the March 24, 2017 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

Seeking Alpha released an article claiming that Banc of California had concealed several connections between it and Jason Galanis, who has been convicted of criminal securities fraud. Specifically, the Complaint maintains that: Banc of California CEO Jason Sugarman was the founder, CEO, and indirect owner of a company controlled by Galanis; and that separately, Galanis controlled Banc of California’s founding shareholder.The Complaint further claims that Banc of California was using an off-balance sheet entity to render loans to insiders.

Then, on November 10, 2016, Banc of California revealed it would be stalling the filing of its Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2016 so that its Special Committee could complete a review into the aforementioned improper relationships and related party transactions. On January 23, 2017, Banc of California stated that the Securities and Exchange Commission is pursuing a formal order of investigation directed at these same issues.

When this news was released to the public, the value of Banc dropped, causing investors harm.

Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC

Brian Lundin, Esq.

Telephone: 888-713-1033

Facsimile: 888-713-1125

brian@lundinlawpc.com

http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 453812

LOS ANGELES, CA / ACCESSWIRE / January 30, 2017 / Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against PixarBio Corporation (“PixarBio” or the “Company”) (OTC PINK: PXRB) concerning possible violations of federal securities laws between October 31, 2016 and January 20, 2017 inclusive (the “Class Period”). Investors, who purchased or otherwise acquired shares during the Class Period, should contact the firm prior to the March 27, 2017 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

On January 23, 2017, the SEC revealed the temporary suspension of trading in the stocks of PixarBio “because the market for the security appears to reflect manipulative or deceptive activities and because of questions regarding the accuracy of assertions by PixarBio in press releases and its Form S-1 concerning, among other things: (1) the company’s business combinations and current shareholders; (2) the identity and qualifications of key shareholders and employees; and (3) the company’s current and prospective development efforts.” When this news was released to the public, the value of PixarBio dropped, causing investors harm.

Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC

Brian Lundin, Esq.

Telephone: 888-713-1033

Facsimile: 888-713-1125

brian@lundinlawpc.com

http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 453811